LGND

Ligand Pharmaceuticals Incorporated · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-27

Figures on this page computed 2026-11-08 12:48 UTC

Last close

316.13USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-27

47.5xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
46.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
18.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-08-07
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.13 against 0.37 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.50x

1.27x

0.66x

n/a

3.19x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Sales1.50x
Its own average over 10 years, 179.0M.
Profit1.27x
Its own average over 10 years, 97.7M.
Free cash flow0.66x
Its own average over 10 years, 73.7M.
Debtn/a
Its own average over 1 year, 650.3M.
Price3.19x
Its own average over 11 years, 99. Market data, 2026-11-04

Price is furthest from its own average, at 3.19 times.

Sales is 1.50 times its own 10-year average; Profit is 1.27 times its own 10-year average; Free cash flow is 0.66 times its own 10-year average; Price is 3.19 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Sales against its own 10-year average1.50
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Profit against its own 10-year average1.27
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Free cash flow against its own 10-year average0.66
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Debt against its own 1-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0000886163-26-000006
Reported in
USD
The filing itself
Price against its own 11-year average3.19Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD